<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040465</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00117303</org_study_id>
    <nct_id>NCT04040465</nct_id>
  </id_info>
  <brief_title>Asprin Dosing Estimator in Healthy Adults</brief_title>
  <official_title>Asprin Dosing Estimator in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Understanding sources of variability in human drug dosing is important to the beneficial and&#xD;
      safe use of any drug. Understanding and applying the science of individualizing a drug dose&#xD;
      to a patient is called precision medicine.&#xD;
&#xD;
      Aspirin is one of the oldest most utilized medications for its ability to lower fever,&#xD;
      relieve pain, and to reduce the stickiness of platelets (tiny blood cells that help your body&#xD;
      form clots to stop bleeding. Aspirin dosing is currently the same for all patients and is not&#xD;
      individualized. In the last century, aspirin has shown benefit in reducing cancer, stroke,&#xD;
      and preventing cardiovascular events after one has already had a heart attack or stroke.&#xD;
      Previous human studies have not found consistent positive effects of aspirin when dosed by&#xD;
      body weight. Therefore, how should aspirin be dosed in 2019? Aspirin resistance is the&#xD;
      failure of aspirin to reduce platelet stickiness and thin the blood and most importantly, is&#xD;
      associated with higher risk of heart attacks and strokes. Aspirin resistance may occur due to&#xD;
      not taking aspirin on a regular basis, differences in how platelets behave in some persons,&#xD;
      use of over the counter pain medicines like Motrin®, reduced amount of drug in the body,&#xD;
      and/or a lack of being able to predict a dose for a certain individual.&#xD;
&#xD;
      To find out the best way to dose aspirin, the investigators propose to study healthy&#xD;
      volunteers (persons without any known disease) with different ages and body sizes to see if&#xD;
      aspirin blood levels are tied to platelet stickiness. This information will be used to&#xD;
      mathematically build a computer-based picture of aspirin dosing that will help physicians&#xD;
      pick the best dose of aspirin for each patient. The investigators will then extend studies&#xD;
      for the aspirin dose estimator to be used in other countries in people with heart problems&#xD;
      and stroke, recording future events in a randomized (i.e., coin toss) manner, to determine if&#xD;
      the ability of the aspirin dose estimator to prevent future heart attacks and stroke compared&#xD;
      to people receiving aspirin doses that were chosen without the estimator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM 1: Determine urine TXB2, platelet aggregation function testing (VerifyNow® ASA Test),&#xD;
      salicylate level, CBC with differential, and hs-CRP, in 18 healthy volunteers across BMI&#xD;
      classes of 22-25 (Normal Weight), &gt;25-30 (Overweight), and &gt; 30 kg/m2 (Obese).Total enrolled&#xD;
      cohort: 60 patients and planned treatment cohort: 54 completed patients (anticipated dropout&#xD;
      rate of 10% = 6 patients). The investigators have powered this sample size based on estimates&#xD;
      of effect sizes from published studies examining platelet activation in patients across a&#xD;
      range of BMIs and assuming an alpha = 0.05, with 80% power. In addition, height and weight as&#xD;
      predictors will be evaluated independently of BMI. BMI patient groups (22-25, &gt;25-30, and &gt;&#xD;
      30 kg/m2) will be randomized to low-dose ASA (81mg standard-release), moderate dose ASA&#xD;
      (325mg) or high dose ASA (500mg) (6 patients/each dose).&#xD;
&#xD;
      All patients will have a CBC with differential (to measure blood cell counts including&#xD;
      platelets) and hs-CRP at baseline, serial urine TXB2 (-1, and 2 and 5 hours post ASA dose),&#xD;
      platelet aggregation function testing using VerifyNow® ASA Test 15 min post ASA dose, serial&#xD;
      salicylate levels (0, 15&quot;, 2 hours post-ASA dose) and again 10-14 days after chronic dosing&#xD;
      (urine TXB2 2 hours post ASA dose and platelet aggregation function testing using VerifyNow®&#xD;
      Test 15 min post ASA dose only).&#xD;
&#xD;
      AIM 2: Model associations between construct variables (BMI and aspirin dose) with predictive&#xD;
      variables as collected in AIM 1. Multiple and Linear Regression with backward selection will&#xD;
      be used. In addition, a Structured Equation Model will be applied to the data. Statistical&#xD;
      assessment of model fit will be conducted for all models.&#xD;
&#xD;
      AIM 3: Build an Aspirin Dose Estimator to predict aspirin dosing. Model associations from AIM&#xD;
      2 will create demand estimates that will feed into a user-friendly aspirin dosage estimator.&#xD;
      The simulator will comprise: 1) Entry: An entry screen. In this screen the user will enter&#xD;
      the features of patient clinical information attributes. The user then clicks a 'run' button.&#xD;
      2) Demand Output: The simulator will then create an output screen that will show graphically&#xD;
      aspirin dosing options.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We will place patients into 3 different groups based on BMI, and within those groups patients will be randomly assigned to an aspirin dose (81mg, 325mg, or 500mg)</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Used to measure BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Used to measure BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine TBX2 Collection (Thromboxane levels)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Thromboxane levels measured for indicator of platelet aggregation function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Salicylate Levels</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Used to measure amount of systemic aspirin to compare with TBX2 and BMI categories</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspirin Reaction Units (ARU)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Number given from Verifynow device that will be used to determine platelet aggregation function by arachidonic acid induced aggregation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Count (CBC)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Safety measure labs taken on 2 visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Measured as an inflammatory marker and indicator of cardiac risk and risk of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (mmHg)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Safety measure taken on 2 visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (BPM)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Safety measure taken on 2 visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate (breaths per minute)</measure>
    <time_frame>2 weeks per participant</time_frame>
    <description>Safety measure taken on 2 visits</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Aspirin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Normal Weight/Low Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 22-25 kg/m^2 &amp; receiving 81mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Weight/Normal Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 25-30 kg/m^2 &amp; receiving 325mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Weight/High Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI &gt; 30 kg/m^2 &amp; receiving 500mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/Low Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 22-25 kg/m^2 &amp; receiving 81mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/Normal Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 25-30 kg/m^2 &amp; receiving 325mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/High Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI &gt; 30 kg/m^2 &amp; receiving 500mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese/Low Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 22-25 kg/m^2 &amp; receiving 81mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese/Normal Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI 25-30 kg/m^2 &amp; receiving 325mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese/High Dose Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BMI &gt; 30 kg/m^2 &amp; receiving 500mg Aspirin daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.</description>
    <arm_group_label>Normal Weight/High Dose Aspirin</arm_group_label>
    <arm_group_label>Normal Weight/Low Dose Aspirin</arm_group_label>
    <arm_group_label>Normal Weight/Normal Dose Aspirin</arm_group_label>
    <arm_group_label>Obese/High Dose Aspirin</arm_group_label>
    <arm_group_label>Obese/Low Dose Aspirin</arm_group_label>
    <arm_group_label>Obese/Normal Dose Aspirin</arm_group_label>
    <arm_group_label>Overweight/High Dose Aspirin</arm_group_label>
    <arm_group_label>Overweight/Low Dose Aspirin</arm_group_label>
    <arm_group_label>Overweight/Normal Dose Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18-55 years old (male or female)&#xD;
&#xD;
          -  Healthy Volunteers (medication free without acute or chronic significant health&#xD;
             problems or pathologies)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of asthma&#xD;
&#xD;
          -  History of chronic bronchitis&#xD;
&#xD;
          -  History of emphysema&#xD;
&#xD;
          -  History of renal impairment (eGFR &lt; 30 ml/min)&#xD;
&#xD;
          -  History of hypertension (reviewed by study staff)&#xD;
&#xD;
          -  History of hyperlipidemia&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  History of smoking (within last month)&#xD;
&#xD;
          -  Current depression or anxiety requiring medication therapy&#xD;
&#xD;
          -  Inability to finish the study for any reason&#xD;
&#xD;
          -  Any current pathological condition outside of normal range&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt; 150 K/µL)&#xD;
&#xD;
          -  Other known platelet disorders (eg. von Willebrand disease, Glanzmann thrombasthenia,&#xD;
             Bernard-Soulier Syndrome)&#xD;
&#xD;
          -  Current use of dipyradamole, PGY 12 inhibitors, NSAIDs&#xD;
&#xD;
          -  Or as otherwise determined by the investigative team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Munger, PhD</last_name>
    <phone>8015816165</phone>
    <email>mark.munger@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isaac Nay</last_name>
    <phone>8014484191</phone>
    <email>isaac.nay@pharm.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A Munger, Pharm.D.</last_name>
      <phone>801-581-6165</phone>
      <email>mmunger@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Rondina, M.D.</last_name>
      <phone>8015878308</phone>
      <email>matthew.rondina@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>mark munger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

